IPO Year: 2022
Exchange: NASDAQ
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
8-K/A - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)
CEO Leonard Mazur to present on Tuesday, September 10, 2024, at 9:00 am ET CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), today announced that Chairman and CEO Leonard Mazur will present and host one-on-one investor meetings at the H.C. Wainwright & Co. 26th Annual Global Investment Conference taking place September 9–11, 2024, in New York City. H.C. Wainwright Conference Details: Presentation: 9:00 am ET on Tuesday, September 10, 2024* Location: Lotte New York Palace Hotel, New York City Registration: Available on the conference website. 1x1 meetings: Requests available upon registration or by cont
CRANFORD, N.J., Sept. 5, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR) and Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), today announced that LYMPHIR™ has been added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). LYMPHIR is included based on an NCCN Category 2A recommendation which indicates a uniform NCCN consensus that the drug is appropriate as an option for patients with Cutaneous T-cell Lymphoma (CTCL). LYMPHIR (denileukin diftitox-cxdl), a novel immunotherapy for the treatment of
4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
4/A - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
3 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)
SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)
SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)